Daniel Chao, the Co-founder and CEO of Halo Neuroscience, is excited about the launch of its first neurostimulation device, Halo Sport, which is available for pre-order. If you consider that Chao’s previous company, NeuroPace, involved an FDA-approved implant to treat people with epilepsy, it sounds like a major shift. But in a phone interview, Chao shared his view of the neurostimulation market and the challenge companies like his face in targeting direct to consumer and clinical markets and the potential the technology holds for treating a broad range of conditions.
